vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Veris Residential, Inc.（VRE）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Veris Residential, Inc.的1.1倍（$75.5M vs $70.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 3.5%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 1.9%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Veris Residential, Inc.是一家总部位于美国新泽西州泽西城的房地产投资信托企业，核心投资布局集中在新泽西州及波士顿地区的公寓类物业，专注于住宅不动产领域的资产运营与价值管理。
PBYI vs VRE — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$70.1M
营收增速更快
PBYI
高出24.3%
3.5%
两年增速更快
PBYI
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $70.1M |
| 净利润 | — | $-14.0M |
| 毛利率 | 69.3% | 95.9% |
| 营业利润率 | 22.7% | -22.2% |
| 净利率 | — | -20.0% |
| 营收同比 | 27.7% | 3.5% |
| 净利润同比 | — | -30.9% |
| 每股收益（稀释后） | $0.26 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIVRE
| Q1 26 | — | $70.1M | ||
| Q4 25 | $75.5M | $71.3M | ||
| Q3 25 | $54.5M | $73.4M | ||
| Q2 25 | $52.4M | $75.9M | ||
| Q1 25 | $46.0M | $67.8M | ||
| Q4 24 | $59.1M | $68.1M | ||
| Q3 24 | $80.5M | $68.2M | ||
| Q2 24 | $47.1M | $67.5M |
净利润PBYIVRE
| Q1 26 | — | $-14.0M | ||
| Q4 25 | — | $-203.0K | ||
| Q3 25 | $8.8M | $75.2M | ||
| Q2 25 | $5.9M | $10.9M | ||
| Q1 25 | $3.0M | $-10.7M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | $20.3M | $-9.7M | ||
| Q2 24 | $-4.5M | $2.9M |
毛利率PBYIVRE
| Q1 26 | — | 95.9% | ||
| Q4 25 | 69.3% | 97.2% | ||
| Q3 25 | 77.7% | 96.8% | ||
| Q2 25 | 76.5% | 97.2% | ||
| Q1 25 | 77.1% | 95.9% | ||
| Q4 24 | 76.4% | 97.1% | ||
| Q3 24 | 63.9% | 96.9% | ||
| Q2 24 | 77.4% | 97.3% |
营业利润率PBYIVRE
| Q1 26 | — | -22.2% | ||
| Q4 25 | 22.7% | -0.9% | ||
| Q3 25 | 17.6% | — | ||
| Q2 25 | 12.7% | 15.8% | ||
| Q1 25 | 8.7% | -20.4% | ||
| Q4 24 | 22.6% | -21.9% | ||
| Q3 24 | 27.4% | -16.2% | ||
| Q2 24 | -4.6% | 2.2% |
净利率PBYIVRE
| Q1 26 | — | -20.0% | ||
| Q4 25 | — | -0.3% | ||
| Q3 25 | 16.2% | 102.4% | ||
| Q2 25 | 11.2% | 14.4% | ||
| Q1 25 | 6.5% | -15.8% | ||
| Q4 24 | — | -18.3% | ||
| Q3 24 | 25.2% | -14.2% | ||
| Q2 24 | -9.6% | 4.3% |
每股收益（稀释后）PBYIVRE
| Q1 26 | — | $-0.15 | ||
| Q4 25 | $0.26 | $0.00 | ||
| Q3 25 | $0.17 | $0.80 | ||
| Q2 25 | $0.12 | $0.12 | ||
| Q1 25 | $0.06 | $-0.12 | ||
| Q4 24 | $0.40 | $-0.14 | ||
| Q3 24 | $0.41 | $-0.10 | ||
| Q2 24 | $-0.09 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $9.4M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $1.1B |
| 总资产 | $216.3M | $2.7B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIVRE
| Q1 26 | — | $9.4M | ||
| Q4 25 | $97.5M | $14.1M | ||
| Q3 25 | $94.4M | $8.8M | ||
| Q2 25 | $96.0M | $11.4M | ||
| Q1 25 | $93.2M | $7.6M | ||
| Q4 24 | $101.0M | $7.3M | ||
| Q3 24 | $96.7M | $12.8M | ||
| Q2 24 | $96.8M | $18.4M |
总债务PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | $1.4B | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | $1.7B | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
股东权益PBYIVRE
| Q1 26 | — | $1.1B | ||
| Q4 25 | $130.3M | $1.2B | ||
| Q3 25 | $115.3M | $1.2B | ||
| Q2 25 | $104.7M | $1.1B | ||
| Q1 25 | $97.1M | $1.1B | ||
| Q4 24 | $92.1M | $1.1B | ||
| Q3 24 | $71.1M | $1.1B | ||
| Q2 24 | $48.5M | $1.1B |
总资产PBYIVRE
| Q1 26 | — | $2.7B | ||
| Q4 25 | $216.3M | $2.7B | ||
| Q3 25 | $202.9M | $2.8B | ||
| Q2 25 | $194.9M | $3.1B | ||
| Q1 25 | $196.2M | $3.0B | ||
| Q4 24 | $213.3M | $3.0B | ||
| Q3 24 | $220.7M | $3.0B | ||
| Q2 24 | $205.0M | $3.0B |
负债/权益比PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | 0.17× | 1.18× | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | 1.52× | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $14.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIVRE
| Q1 26 | — | $14.0M | ||
| Q4 25 | $14.4M | $76.0M | ||
| Q3 25 | $9.7M | $13.5M | ||
| Q2 25 | $14.1M | $23.8M | ||
| Q1 25 | $3.6M | $13.2M | ||
| Q4 24 | $15.6M | $52.3M | ||
| Q3 24 | $11.0M | $13.9M | ||
| Q2 24 | $1.0M | $10.8M |
自由现金流PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — |
自由现金流率PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — |
资本支出强度PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率PBYIVRE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 0.18× | ||
| Q2 25 | 2.41× | 2.18× | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | 3.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
